Market Intelligence chevron_right Pharma & Healthcare chevron_right Cancer Biosimilar Monoclonal Antibodies
Global Report 2025

Global Cancer Biosimilar Monoclonal Antibodies Market Growth (Status and Outlook) 2025-2031

calendar_todayPublished: May 2025 descriptionPages: 135 categoryCategory: Pharma & Healthcare
cloud_downloadRequest Sample Report
mailPre-Order Enquiry
local_offerGet Discount

The global Cancer Biosimilar Monoclonal Antibodies market size is predicted to grow from US$ 7120 million in 2025 to US$ 14370 million in 2031; it is expected to grow at a CAGR of 12.4% from 2025 to 2031.

Cancer biosimilar monoclonal antibodies refer to biological products developed through strict approval procedures after the expiration of the original monoclonal antibody drug patent, which are highly similar in quality, safety, and efficacy to the original drug. These generic products are not simple chemical generic drugs, but rather large molecule protein drugs produced through complex biotechnology processes, specifically targeting specific antigen targets in cancer treatment.

The global market for cancer biosimilar monoclonal antibodies has shown a rapid growth trend in recent years. Europe is currently the leading market for cancer biosimilar monoclonal antibodies, thanks to early policy support and a mature reimbursement system. Although the US market started relatively late, its growth rate has been astonishing in recent years. The active approval attitude of the FDA and the adjustment of medical insurance payment policies have driven market expansion. The Asian market, with China and India as its core growth engines, demonstrates explosive growth potential. The global market has formed a multi-level competitive structure.

Segmentation by Type:

  • Mouse Derived Monoclonal Antibody
  • Human Mouse Chimeric Monoclonal Antibody
  • Human Derived Monoclonal Antibody
  • Fully Human Derived Monoclonal Antibody

Segmentation by Application:

  • Solid Tumor Treatment
  • Hematological System Tumor Treatment
  • Combination Therapy

Market by Region:

  • Americas
  • APAC
  • Europe
  • Middle East & Africa

Company's Coverage:

  • Amgen
  • Samsung Bioepis
  • Sandoz
  • Roche
  • Merck
  • Pfizer
  • Mylan
  • BristolMyers Squibb
  • Celltrion
  • Biocon
  • AbbVie
  • Teva Pharmaceutical Industries
  • Henlius
  • Innovent Biologics
  • Qilu Pharmaceutical
  • Sunshine Guojian
  • Bio-Thera Solutions
  • Biotech Pharma
  • Junshi Biosciences

Key Questions Addressed in this Report:

Frequently Asked Questions

What is the USP of the report? expand_more
Cancer Biosimilar Monoclonal Antibodies report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
What are the key content of the report? expand_more
Cancer Biosimilar Monoclonal Antibodies report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
What are the value propositions and opportunities offered in this market research report? expand_more
Cancer Biosimilar Monoclonal Antibodies report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.